Experienced in Teratoma of the Mediastinum

Dr. Carl R. Gray

Oncology
Ogden, UT 
Accepting New Patients
30 Years of Experience
Experienced in Teratoma of the Mediastinum
Ogden, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carl Gray is an Oncologist in Ogden, Utah. Dr. Gray has been practicing medicine for over 30 years and is rated as an Experienced provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Childhood Iron Deficiency Anemia, and Paget Disease of the Breast. Dr. Gray is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Texas Health Science Center, 1995
Residency
University of California Davis Medical Center
Specialties
Oncology
Licenses
Internal Medicine in UT
Board Certifications
American Board Of Internal Medicine
Fellowships
University of California Davis Medical Center
Hospital Affiliations
Layton Hospital
McKay Dee Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Utah Hematology Oncology - 400 E
Ogden, UT 84405
Other Locations
Utah Hematology Oncology - Layton
2132 North Robins Drive, Suite 301, Layton, UT 84041
Ogden Clinic - Bountiful
Bountiful, UT 84010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Biological, Drug
Study Drugs: Dostarlimab, Niraparib
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: June 06, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 5 Less Clinical Trials

1 Total Publications

Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards.
Journal: International journal of surgical oncology
Published: May 28, 2011
Similar Doctors
Advanced in Teratoma of the Mediastinum
Dr. Scott J. Samuelson
Oncology | Hematology | Hematology Oncology
Advanced in Teratoma of the Mediastinum
Dr. Scott J. Samuelson
Oncology | Hematology | Hematology Oncology

Utah Cancer Specialists PC

520 Medical Dr, Suite 340, 
Bountiful, UT 
 (19.2 miles away)
801-296-6665
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Samuelson is an Oncologist and a Hematologist in Bountiful, Utah. Dr. Samuelson is rated as an Advanced provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Familial Colorectal Cancer, and Non-Hodgkin Lymphoma. Dr. Samuelson is currently accepting new patients.

Experienced in Teratoma of the Mediastinum
Dr. David M. Gill
Oncology
Experienced in Teratoma of the Mediastinum
Dr. David M. Gill
Oncology

Intermountain Health Cancer Center - Murray

5171 South Cottonwood Street, Suite 610, 
Murray, UT 
 (34.6 miles away)
801-507-3630
Experience:
11+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Gill is an Oncologist in Murray, Utah. Dr. Gill has been practicing medicine for over 11 years and is rated as a Distinguished provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Orchiectomy, and Prostatectomy. Dr. Gill is currently accepting new patients.

Experienced in Teratoma of the Mediastinum
Dr. Belisario A. Arango
Oncology
Experienced in Teratoma of the Mediastinum
Dr. Belisario A. Arango
Oncology

Utah Cancer Specialists - Ogden

Ogden, UT 
 (0.1 miles away)
385-423-2855
Experience:
18+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Belisario Arango is an Oncologist in Ogden, Utah. Dr. Arango has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Hemochromatosis. Dr. Arango is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gray's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 66 Advanced Conditions
    View All 161 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile